Roche / Genentech clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
85 trials changed in the last 30 days: 2 stopped, 24 with notable changes, 59 with minor changes only.
- Minor: CEVOLUTION · Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care · Previously Treated Multiple Myeloma Primary completion pushed from Oct 31, 2028 to Nov 30, 2028
- Minor: MorningSun · Mosunetuzumab Monotherapy · Select B-Cell Malignancies Primary completion pushed from Jul 31, 2027 to Oct 1, 2027
- Stopped: See How RO7763505 Works and How Safe it is When Given to Healthy People and · Stable Heart Disease Trial terminated
- Minor: STARTRK-2 · Basket Study of Entrectinib (RXDX-101) · Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Trial completed
- Minor: dRAvite-LTE · Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations
- Notable: RO7821657 · Solid Tumors Recruitment opened
- Minor: WILL-EMI · Emicizumab · Type 3 Von Willebrand Disease Primary completion pushed from Apr 30, 2027 to Oct 6, 2027
- Minor: SOLUNA · Mosunetuzumab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Primary completion pushed from Feb 28, 2028 to Aug 11, 2028
- Minor: ZUPREME-5 · Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations
- Notable: ZEBRHA 3 · NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children Recruitment opened
- Notable: Inavolisib and Fulvestrant With or Without Palbociclib · Advanced Breast Cancer (ABC) and Type 2 Diabetes Start date pushed from Oct 30, 2026 to Nov 30, 2026
- Minor: Astegolimab · Chronic Obstructive Pulmonary Disease (COPD) Enrollment closed, study ongoing
- Minor: INAVO122 · Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo · PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer Primary completion pushed from Dec 31, 2026 to May 3, 2027
- Notable: ALLEGORY · Obinutuzumab · Systemic Lupus Erythematosus Results posted: Nov 12, 2026
- Notable: Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide · Type 2 Diabetes Enrollment reopened
- Minor: Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant · ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Trial sites expanded: 8 → 13 locations
- Minor: Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib · Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Study completion pushed from Jul 31, 2027 to Jul 28, 2028
- Minor: Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 · B-Cell Non-Hodgkin Lymphoma Primary and study completion moved earlier from Aug 5, 2029 to Apr 30, 2029
- Notable: Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Primary completion pushed from Jan 31, 2027 to Jul 31, 2029
- Notable: GDC-7035 With Anti-Cancer Therapies · KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma Start date pushed from Oct 31, 2026 to Nov 30, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07937852 A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants… | Phase 3 | Not Yet Recruiting |
| 2026-11-05 | NCT07918846 A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity… | Phase 3 | Not Yet Recruiting |
| 2026-10-30 | NCT07905924 A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or… | Phase 1 | Not Yet Recruiting |
| 2026-10-22 | NCT07889648 A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in… | Phase 3 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 54 | |
| Phase 1/2 | 23 | |
| Phase 2 | 50 | |
| Phase 2/3 | 3 | |
| Phase 3 | 91 | |
| Phase 4 | 9 |
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 47
Breast Cancer (29) · Multiple Sclerosis (25) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (16) · Non-Hodgkin Lymphoma (14) · Obesity (12) · Dementia (11) · Multiple Myeloma (10) · Diabetes (9) · Alzheimer's Disease (8)
Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.